.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Novartis
Daiichi Sankyo
Moodys
Merck
Farmers Insurance
Citi
Boehringer Ingelheim
Fish and Richardson

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205636

« Back to Dashboard
NDA 205636 describes PROAIR RESPICLICK, which is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from one supplier. There are twelve patents protecting this drug. Additional details are available on the PROAIR RESPICLICK profile page.

The generic ingredient in PROAIR RESPICLICK is albuterol sulfate. There are thirty-seven drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the albuterol sulfate profile page.

Summary for 205636

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:12
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 205636

Mechanism of ActionAdrenergic beta2-Agonists

Suppliers and Packaging for NDA: 205636

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PROAIR RESPICLICK
albuterol sulfate
POWDER, METERED;INHALATION 205636 NDA Teva Respiratory, LLC 59310-580 59310-580-20 1 INHALER in 1 BOX (59310-580-20) > 200 POWDER, METERED in 1 INHALER
PROAIR RESPICLICK
albuterol sulfate
POWDER, METERED;INHALATION 205636 NDA Teva Respiratory, LLC 59310-580 59310-580-21 1 INHALER in 1 BOX (59310-580-21) > 200 POWDER, METERED in 1 INHALER

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER, METERED;INHALATIONStrengthEQ 0.090MG BASE/INH
Approval Date:Mar 31, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Apr 28, 2019
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Regulatory Exclusivity Expiration:Mar 12, 2018
Regulatory Exclusivity Use:NEW PRODUCT
Patent:► SubscribePatent Expiration:Dec 18, 2017Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Citi
Fish and Richardson
Cantor Fitzgerald
Chubb
Moodys
QuintilesIMS
Accenture
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot